A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.
Sponsor: BeiGene
Listed as NCT06697184, this PHASE1/PHASE2 trial focuses on CLL and Chronic Lymphocytic Leukemia and remains ongoing. Sponsored by BeiGene, it has been updated 11 times since 2025, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 6 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BeiGene
For direct contact, visit the study record on ClinicalTrials.gov .